All In Biotech

Drug Trial Radar · NCT03511664

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Last checked: Nov 20, 2026Latest source record: Jan 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 861 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

861

Actual

Start

May 29, 2018

Primary completion

Jan 27, 2021

Study completion Dec 14, 2023

Sponsor

Lead sponsor
EndocyteIndustry
Sponsor type
Industry
First posted
Apr 30, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study was to compare the two alternate primary endpoints of radiographic progression-free survival (rPFS) and overall survival (OS) in patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who received 177Lu-PSMA-617 in addition to best supportive/best standard of care (BSC/BSoC) versus patients treated with best supportive/best standard of care alone.

Conditions

  • Prostate Cancer

Interventions

  • 177Lu-PSMA-617Drug

    Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles. After 4 cycles, patients were assessed for (1) evidence of response, (2) residual disease, and (3) tolerance to 177Lu-PSMA-617. If all 3 assessments were met the patient might received an additional 2 cycles of 177Lu-PSMA-617.

  • Best supportive/best standard of careOther

    Best supportive/best standard of care as defined by the local investigator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiographic Progression-free Survival (rPFS)Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 32 months (Primary Analysis cut-off date = 27-Jan-2021)
  2. Overall Survival (OS)Time frame: From date of randomization until date of death from any cause, assessed up to 32 months (Primary Analysis cut-off date = 27-Jan-2021) and up to 66 months (Final Analysis cut-off date = 14-Dec-2023)

Locations

88 sites in 10 countries. Site status is shown where the registry gives one.

  • HonorHealth Research Institute

    Scottsdale, Arizona

  • University of Arizona Cancer Center

    Tucson, Arizona

  • VA Greater Los Angeles Healthcare System

    Los Angeles, California

  • University of California Los Angeles, Nuclear Medicine

    Los Angeles, California

  • Stanford Cancer Institute

    Palo Alto, California

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • University of Colorado Hospital

    Aurora, Colorado

  • Yale Cancer Center

    New Haven, Connecticut

  • Washington DC VA Medical Center, Nuclear Medicine Service

    Washington D.C., District of Columbia

  • H. Lee Moffitt Cancer Center & Research Institute

    Tampa, Florida

  • Northwestern University

    Chicago, Illinois

  • Parkview Research Center

    Fort Wayne, Indiana

  • Indiana University Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Iowa City VA Medical Center

    Iowa City, Iowa

  • Norton Cancer Institute

    Louisville, Kentucky

  • Tulane Medical Center, Tulane Cancer Center

    New Orleans, Louisiana

  • University of Maryland Greenebaum Cancer Center

    Baltimore, Maryland

  • Chesapeake Urology Associates (CUA) P.A.

    Towson, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • VA Ann Arbor Healthcare System

    Ann Arbor, Michigan

  • University of Michigan Hospitals

    Ann Arbor, Michigan

  • Karmanos Cancer Center

    Detroit, Michigan

  • Mayo Clinic - Rochester

    Rochester, Minnesota

  • Saint Louis University Hospital

    St Louis, Missouri

  • VA St. Louis Health Care System - John Cochran

    St Louis, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • XCancer Omaha / Urology Cancer Center

    Omaha, Nebraska

  • Comprehensive Cancer Centers of Nevada - Twain Office

    Las Vegas, Nevada

  • Regional Cancer Care Associates, Central Jersey Division

    East Brunswick, New Jersey

  • New Mexico Oncology Hematology Consultants Ltd., New Mexico Cancer Center

    Albuquerque, New Mexico

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • New York Presbyterian Hospital/Weill Cornell Medical Center

    New York, New York

  • Duke University Medical Center, Duke Cancer Center

    Durham, North Carolina

  • Greater Dayton Cancer Center

    Kettering, Ohio

  • Oregon Health and Science University, Nuclear Medicine

    Portland, Oregon

  • Pennsylvania Cancer Specialists & Research Institute

    Gettysburg, Pennsylvania

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.